103853-88-9

Basic information

• Product Name: 4-HYDROXY-2-METHYL-QUINOLINE-6-CARBOXYLIC ACID
• Synonyms: TIMTEC-BB SBB011040;4-HYDROXY-2-METHYL-QUINOLINE-6-CARBOXYLIC ACID;4-Hydroxy-2-methyl-6-quinolinecarboxylic acid
• CAS NO: 103853-88-9
• Molecular Formula: C₁₁H₉NO₃
• Molecular Weight: 203.19
• Mol File: 103853-88-9.mol

Chemical Properties

• Melting Point: >300 °C
• Boiling Point: 404.3°C at 760 mmHg
• Flash Point: 198.3°C
• Appearance: /
• Density: 1.331g/cm³
• Vapor Pressure: 2.92E-07mmHg at 25°C
• Refractive Index: 1.613
• PKA: 3.24±0.30(Predicted)
• CAS DataBase Reference: 4-HYDROXY-2-METHYL-QUINOLINE-6-CARBOXYLIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 4-HYDROXY-2-METHYL-QUINOLINE-6-CARBOXYLIC ACID(103853-88-9)
• EPA Substance Registry System: 4-HYDROXY-2-METHYL-QUINOLINE-6-CARBOXYLIC ACID(103853-88-9)

Safety Data

• Hazard Codes: Xi
• HazardClass: IRRITANT
• Hazardous Substances Data: 103853-88-9(Hazardous Substances Data)

Usage

Synthesis Reference(s)

Journal of Medicinal Chemistry, 43, p. 4667, 2000 DOI: 10.1021/jm0002073Journal of the American Chemical Society, 77, p. 6682, 1955 DOI: 10.1021/ja01629a106

InChI:InChI=1/C11H9NO3/c1-6-4-10(13)8-5-7(11(14)15)2-3-9(8)12-6/h2-5H,1H3,(H,12,13)(H,14,15)

Upstream product

• 141-97-9 ethyl acetoacetate 
• 150-13-0 4-amino-benzoic acid 
• 141890-72-4 ethyl 3-(4-ethoxycarbonyl)phenylaminocrotonate 
• 94-09-7 p-aminoethylbenzoate 
• 593287-13-9 ethyl 4-hydroxy-2-methylquinoline-6-carboxylate 
• 108877-58-3 4-(2-ethoxycarbonyl-1-methyl-vinylamino)-benzoic acid 
• 100136-28-5 4-methoxy-2-methyl-quinoline-6-carbonitrile 

Downstream Products

• 137872-96-9 4-amino-2-methylquinoline-6-carboxylic acid benzylamide 
• 321534-85-4 4-methoxyquinoline-6-carboxamide 
• 321534-84-3 4-hydroxy-2-methyl-quinoline-6-carboxylic acid (2-phenoxymethyl-phenyl)-amide 
• 941252-09-1 N-benzyl-4-hydroxy-2-methylquinoline-6-carboxamide 
• 450379-86-9 2-methyl-4-oxo-1,4-dihydro-quinoline-6-carboxylic acid methyl ester 

Relevant articles and documents

MONOACYLGLYCEROL LIPASE MODULATORS

Fused and bridged compounds of Formula (I), and pharmaceutically acceptable salts, isotopes, N-oxides, solvates, and stereoisomers thereof, pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with MGL modulation, such as those associated with pain, psychiatric disorders, neurological disorders (including, but not limited to major depressive disorder, treatment resistant depression, anxious depression, autism spectrum disorders, Asperger syndrome, bipolar disorder), cancers and eye conditions: (I) wherein R1a, R1b, R2, and R3, are defined herein.

2-PROPENE-1-ONES AS HSP 70 INDUCERS

The present invention relates to novel compounds of 2-propene-1-one series, of general formula (I), their derivatives, analogs, tautomeric forms, stereoisomers, polymorphs, pharmaceutically acceptable salts, pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them, wherein R5, R6, Q and Y are as defined in the specification. The present invention also relates to a process for preparing such compounds, compositions containing such compounds, and use of such compound and composition in medicine. The compounds of the general formula (I) induce HSP-70 and are useful for the treatment of diseases accompanying pathological stress in a living mammalian organism, including a human being, such as stroke, myocardial infarction, inflammatory disorder, hepatotoxicity, sepsis, diseases of viral origin, allograft rejection, tumourous diseases, gastric mucosal damage, brain haemorrhage, endothelial dysfunctions, diabetic complications, neuro-degenerative diseases, post-traumatic neuronal damage, acute renal failure, glaucoma and aging related skin degeneration.

4-Aminoquinolines: Novel nociceptin antagonists with analgesic activity

Small-molecule nociceptin antagonists were synthesized to examine their therapeutic potential. After a 4-aminoquinoline derivative was found to bind with the human ORL1 receptor, a series of 4-aminoquinolines and related compounds were synthesized and their binding was evaluated. Elucidation of structure - Activity relationships eventually led to the optimum compounds. One of these compounds, N-(4-amino-2-methylquinolin-6-yl)-2-(4-ethylphenoxymethyl)benzamide hydrochloride (11) not only antagonized nociceptin-induced allodynia in mice but also showed analgesic effect in a hot plate test using mice and in a formalin test using rats. Its analgesic effect was not antagonized by the opioid antagonist naloxone. These results indicate that this nociceptin antagonist has the potential to become a novel type of analgesic that differs from μ-opioid agonists.